Exosome Diagnostics, Inc.

Dalin Chan

Robert Kitchen

Johan Skog

Wei Yu

Vasisht Tadigotla

James Hurley

Michael Valentino

Sudipto Chakrabortty

Elena Castellanos-Rizaldos

Dominik Grimm

Georg Stoll

Mia Sher

The present disclosure relates to methods for detecting and treating bladder cancer in a subject using the gene expression level measurements from exosomes derived from the subject.

Methods for developing urine biomarkers and for detecting bladder cancer

The invention provides a series of steps that prepare nucleic acids (RNA and/or DNA) isolated from extracellular vesicles for sequencing. This enables a wide diversity of RNAs and/or DNAs, to be efficiently detected. These can then be used to identify various attributes such as gene expression, alternative splicing, and the detection of both somatic and germline mutations including single nucleotide variants (SNV) and structural variations (insertions/deletions, fusions, inversions).

Sequencing and analysis of exosome associated nucleic acids

The present disclosure relates to methods for treating glioblastoma in a subject in need thereof using gene signatures in exosomal RNA derived from the subject. The gene signatures comprise: at least one of FAM229B, ZNF35, CTD-2647L4.4, CABP5, CYP20A1, CEP126, DTX2P1-UPK3BP1-PMS2P11, RP11-507K12.1, KRBA2, CALD1, LRFN1, RP2, SLC2A13, CDKL3, SLC8A3, ANTXR2, TIGD5, AC074289.1 RP11-932O9.7; at least one of tRNA-Lys-CTT-2-2, tRNA-Pro-AGG-2-7, LAMTOR2, RAD51AP1, DENND2A, A1BG, THSD1, CSF1, RP11-332M2.1, ZNF717, ZNF860, ORC6, Clorf50, PSPH, HIST1H4C, CYP2U1, THAP8, TMEM192, NAA20; or at least one of CREBBP, CXCR2 and S100A9. The treatment methods comprise measuring the expression level of at least one of the aforementioned genes in exosomal RNA from a subject and administering to the subject a glioblastoma treatment based on the expression level(s).

Methods of treating glioblastoma in a subject informed by exosomal RNA signatures

Growing community of inventors

Brighton, MA, United States of America

Dalin Chan